# US 2014/0275270 A1 · Isolated Stereoisomeric Forms Of (S)2-N(3-O-(Propan 2-Ol)-1-Propyl-4-Hydroxybenzene)-3-Phenylpropylamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275270 A1
- Document ID: US20140275270A1
- Status: Published application
- Kind: A1
- Application number: 14/291,901
- Filed: 2014-05-30
- Published: 2014-09-18
- Earliest claimed: 2011-12-08
- Assignees: Novaremed Limited
- Applicants: Novaremed Ltd.
- Inventors: Eliahu Kaplan
- Web page: https://patentgrep.com/patent/US20140275270A1

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07C 233/22: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Isolated stereoisomeric forms of the compound (S)2-N(3-O-(propan 2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide and uses in the treatment of pain.

## Claims

### Claim 1

A compound having the following formula (II):
wherein the compound has the specific stereochemistry of (S)2-N(3-O—((S)propan 2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide or a pharmaceutically acceptable salt or hydrate thereof,
wherein the compound is in a substantially pure form.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound comprises at least 90% of (S)2-N(3-O—((S)propan 2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide and less than 10% of other stereoisomeric forms of the compound.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound comprises at least 95% of (S)2-N(3-O—((S)propan 2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide and less than 5% of other stereoisomeric forms of the compound.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound comprises at least 98% of (S)2-N(3-O—((S)propan 2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide and less than 2% of other stereoisomeric forms of the compound.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein said pharmaceutical composition is formulated as a unit dosage form.

### Claim 7 (depends on 5)

The pharmaceutical composition of claim 5, wherein said pharmaceutical composition is formulated for oral administration.

### Claim 8 (depends on 1, 5)

The pharmaceutical composition of claim 5, wherein said composition is formulated as a unit dosage form comprising 0.1 mg to about 500 mg of the compound of claim 1 or a pharmaceutically acceptable salts or hydrates thereof.

### Claim 9 (depends on 1)

A method for treating or preventing pain in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

### Claim 10 (depends on 1, 9)

The method of claim 9, wherein the compound is administered as a pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the pharmaceutical composition is formulated as a unit dosage form.

### Claim 12 (depends on 10)

The method of claim 10, wherein the pharmaceutical composition is formulated for oral administration.

### Claim 13 (depends on 1, 10)

The method of claim 10, wherein the composition is formulated as a unit dosage form comprising 0.1 mg to 500 mg of the compound of claim 1 or pharmaceutically acceptable salt or hydrate thereof.

### Claim 14 (depends on 1, 10)

The method of claim 10, wherein the pharmaceutical composition is administered as a daily dose of 1.0 mg to 15 g of the compound of claim 1 or pharmaceutically acceptable salt or hydrate thereof.

### Claim 15 (depends on 9)

The method of claim 9, wherein the pain is acute or chronic pain.

### Claim 16 (depends on 9)

The method of claim 9, wherein the pain is nociceptive pain.

### Claim 17 (depends on 9)

The method of claim 9, wherein the pain is neuropathic pain.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the neuropathic pain is at least one symptom selected from neuropathic pains in post herpetic neuralgia, trigeminal neuralgia, diabetic neuralgia, cancer pain, persistent postoperative or posttraumatic pain, hyperalgia, allodynia, postthoracotomy pain, CRPS, pain associated with multiple sclerosis, AIDS, thalamic pain, paraplegic pain caused by myelopathy, anesthesia dolorosa and phantom limb pain.
